Title : Incidence, characterization, and clinical impact analysis of peginterferon beta1a immunogenicity in patients with multiple sclerosis in the ADVANCE trial.

Pub. Date : 2016 Jul

PMID : 27366230

1 Functional Relationships(s)
Compound Name
Protein Name
1 BACKGROUND: Efficacy of interferon beta in multiple sclerosis (MS) can be dampened in patients who develop neutralizing antidrug antibodies (NAbs). nabs interferon beta 1 Homo sapiens